Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2009 Feb;10(2):333-43. doi: 10.1517/14656560802677874 .

Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer.

Author information

  • 1University of Hong Kong, Queen Mary Hospital, Department of Surgery, 102 Pokfulam Road, Hong Kong, China. poontp@hkucc.hku.hk

Abstract

BACKGROUND:

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No more than 30% of HCC patients receive curative treatment. Factors limiting curative therapy include tumor size and degree of liver impairment.

OBJECTIVE:

To develop a cure for medium (3.1-5.0 cm) and large (>5 cm) tumors in seriously impaired livers.

METHOD:

Combine radiofrequency ablation (RFA) with lyso-thermosensitive liposomal doxorubicin (LTLD).

RESULTS/CONCLUSIONS:

RFA is used safely in patients with medium/large tumors and severe liver impairment; unclear tumor margins limit its curative efficacy. LTLD concentrates in the liver, where the anti-HCC chemotherapeutic, doxorubicin, is released into tumor margins by hyperthermia. RFA/LTLD can treat Child-Pugh class A-B patients with tumors up to 7 cm, a substantial increase in curable patients.

PMID:
19236203
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk